

atient Information	Creating an Information	Client Information	
	Specimen Information		
OMMENTS: FASTING:YES			
Test Name	In Range Out Of Range	Reference Range	Lal
TESTOSTERONE, FREE (DIALYSIS)			OT 1
TESTOSTERONE, TOTAL, MS	587	250-1100 ng/dL	SL:
Men with clinically sign	nificant hypogonadal symptoms		
	repeatedly in the range of the		
	may benefit from testosterone		
treatment after adequate	e risk and benefits counseling.		
For additional information	ion plange refer to		
For additional informat:	iagnostics.com/faq/TotalTestoster	CORELCMEMS	
	vided for informational/	опененыны	
educational purposes on.	ly.)		
educational purposes on	ly.)		
This test was developed	and its analytical performance		
This test was developed characteristics have been	and its analytical performance en determined by Quest		
This test was developed characteristics have be Diagnostics. It has not	and its analytical performance en determined by Quest been cleared or approved by the		
This test was developed characteristics have be Diagnostics. It has not FDA. This assay has been	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA		
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA		
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA		SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS)	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes.	35 0-155 0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes.	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA	35.0-155.0 pg/mL	SL
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA	35.0-155.0 pg/mL	
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes.		
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27	22-35 %	
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3	22-35 % 4.9-10.5 mcg/dL	
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7)	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3 2.2	22-35 % 4.9-10.5 mcg/dL 1.4-3.8	EN
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7) TSH	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3	22-35 % 4.9-10.5 mcg/dL	
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7) TSH LIPID PANEL, STANDARD	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3 2.2	22-35 % 4.9-10.5 mcg/dL 1.4-3.8 0.40-4.50 mIU/L	EN
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7) TSH	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3 2.2 2.61	22-35 % 4.9-10.5 mcg/dL 1.4-3.8	EN EN
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7) TSH LIPID PANEL, STANDARD CHOLESTEROL, TOTAL	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3 2.2 2.61 155	22-35 % 4.9-10.5 mcg/dL 1.4-3.8 0.40-4.50 mIU/L <200 mg/dL	SL EN EN EN EN EN
This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used TESTOSTERONE, FREE (DIALYSIS) TESTOSTERONE, FREE This test was developed characteristics have bee Diagnostics. It has not FDA. This assay has been regulations and is used THYROID PANEL WITH TSH THYROID PANEL T3 UPTAKE T4 (THYROXINE), TOTAL FREE T4 INDEX (T7) TSH LIPID PANEL, STANDARD CHOLESTEROL, TOTAL HDL CHOLESTEROL	and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 80.7 and its analytical performance en determined by Quest been cleared or approved by the n validated pursuant to the CLIA for clinical purposes. 27 8.3 2.2 2.61 155 43	22-35 % 4.9-10.5 mcg/dL 1.4-3.8 0.40-4.50 mIU/L <200 mg/dL > OR = 40 mg/dL	EN EN EN

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.

calculation, which better accuracy tha	ated using the Martin-Hop is a validated novel methon n the Friedewald equation	od providing	
estimation of LDL-C			
Martin SS et al. JA	MA. 2013;310(19): 2061-200	58	
(http://education.Q	uestDiagnostics.com/faq/Fi	AQ164)	
CHOL/HDLC RATIO	3.6	<5.0 (calc)	EN
NON HDL CHOLESTEROL	112	<130 mg/dL (calc)	EN

SPECIMEN:



Patient Information	Specimen Information	<b>Client Information</b>	
factor, treating to a not	<b>In Range Out Of</b> es plus 1 major ASCVD ris n-HDL-C goal of <100 mg/d	k	Lab
(LDL-C of <70 mg/dL) is option. COMPREHENSIVE METABOLIC	considered a therapeutic		EN
PANEL GLUCOSE	78	65-99 mg/dL	
		Fasting reference interval	
UREA NITROGEN (BUN)	10	7-25 mg/dL	
CREATININE	0.79	0.70-1.35 mg/dL > OR = 60 mL/min/1.73m2	
the new eGFR from a prev result, go to https://ww	100 CKD-EPI 2021 equation. T ious Creatinine or Cystat ø.kidney.org/professional	o calculate in C	
kdoqi/gfr%5Fcalculator BUN/CREATININE RATIO SODIUM	NOT APPLICABLE	6-22 (calc) 135-146 mmol/L	
POTASSIUM	4.4	3.5-5.3 mmol/L	
CHLORIDE CARBON DIOXIDE	105 26	98-110 mmol/L 20-32 mmol/L	
CALCIUM	9.0	8.6-10.3 mg/dL	
PROTEIN, TOTAL	6.7	6.1-8.1  g/dL	
ALBUMIN GLOBULIN	4.1 2.6	3.6-5.1 g/dL 1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.6	1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.4	0.2-1.2  mg/dL	
ALKALINE PHOSPHATASE AST	54 21	35-144 U/L 10-35 U/L	
ALT	16	9-46 U/L	
PHOSPHATE (AS PHOSPHORUS)	3.5	2.5-4.5 mg/dL	EN
URIC ACID Therapeutic target for g	5.0 out patients: <6.0 mg/dL	4.0-8.0 mg/dL	EN
LD	102 L	120-250 U/L	EN
GGT IGF 1, LC/MS	9 115	3-70 U/L 41-279 ng/mL	EN EZ
Z SCORE (MALE)	-0.2	-2.0 - +2.0 SD	
characteristics have been Nichols Institute San Ju cleared or approved by F	and its analytical perfor n determined by Quest Dia an Capistrano. It has not DA. This assay has been v ulations and is used for	gnostics been alidated	
CBC (INCLUDES DIFF/PLT)			EN
WHITE BLOOD CELL COUNT RED BLOOD CELL COUNT	4.1 4.37	3.8-10.8 Thousand/uL 4.20-5.80 Million/uL	
HEMOGLOBIN	13.6	13.2-17.1 g/dL	
HEMATOCRIT	39.3	38.5-50.0 🖗	
MCV	89.9 31.1	80.0-100.0 fL	
MCH MCHC	31.1 34.6	27.0-33.0 pg 32.0-36.0 g/dL	
RDW	12.7	11.0-15.0 %	



Patient Information	Specimen Information		Client Information	
Test Name	In Range	Out Of Range	Reference Range	Lab
PLATELET COUNT MPV	318 10.2		140-400 Thousand/uL 7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	3009		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	0000	570 L	850-3900 cells/uL	
ABSOLUTE MONOCYTES	361		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	119		15-500 cells/uL	
ABSOLUTE BASOPHILS	41		0-200 cells/uL	
NEUTROPHILS	73.4		00	
LYMPHOCYTES	13.9		00	
MONOCYTES	8.8 2.9		olo 0	
EOSINOPHILS BASOPHILS	1.0		5 8	
URINALYSIS, COMPLETE	1.0		•	EN
COLOR	YELLOW		YELLOW	
APPEARANCE		CLOUDY	CLEAR	
SPECIFIC GRAVITY	1.021		1.001-1.035	
PH	6.0		5.0-8.0	
GLUCOSE	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE	A.	NEGATIVE	
KETONES	NECAULTILE	1+	NEGATIVE	
OCCULT BLOOD PROTEIN	NEGATIVE	TRACE	NEGATIVE NEGATIVE	
NITRITE	NEGATIVE	INACE	NEGATIVE	
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	
WBC	NONE SEEN		< OR = 5 /HPF	
RBC	NONE SEEN	~	< OR = 2 /HPF	
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 /HPF	
BACTERIA	NONE SEEN		NONE SEEN /HPF	
HYALINE CAST	NONE SEEN	of MDC	NONE SEEN /LPF	
This urine was analyzed f RBC, bacteria, casts, and				
Only those elements seen				
IRON AND TOTAL IRON BINDING CAPACITY				EN
IRON, TOTAL	147		50-180 mcg/dL	
IRON BINDING CAPACITY	338		250-425 mcg/dL (calc)	
% SATURATION	43		20-48 % (calc)	
PSA, TOTAL	0.15		< OR = 4.00 ng/mL	EN
The total PSA value from				
standardized against the result will be approximat				
to the equimolar-standard				
Coulter). Comparison of s				
interpreted with this fac				
	the of			
This test was performed u chemiluminescent method.				
different assay methods of				
interchangeably. PSA leve		of		
value, should not be inte				



Patient Information	Specimen Information	Client Information

Endocrinology				
Test Nam	e	Result	Reference Range	Lab
VITAMIN D,25-OH,TOTAL,IA		46	30-100 ng/mL	EN
Vitamin D Status	25-OH Vitamin D:			
Deficiency: Insufficiency: Optimal:	<pre>&lt;20 ng/mL 20 - 29 ng/mL &gt; or = 30 ng/mL</pre>			
	patients on D2-supplementation D, (D2,D3), LC/MS/MS is recom		om quantitation of D2 and D3 fractions is required 92888 (patients >2yrs).	d, the

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/ educational purposes only.)

Physician Comments:

## **PERFORMING SITE:**

- EN
- QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: TAB TOOCHINDA,MD, CLIA: 05D0642827 QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA,MD,PHD,MBA, CLIA: 05D0643352 QUEST DIAGNOSTICS NICHOLS VALENCIA, 27027 TOURNEY ROAD, VALENCIA, CA 91355-5386 Laboratory Director: THOMAS MCDONALD,MD, CLIA: 05D0550302 ΕZ
- SLI